-
Mashup Score: 12Trastuzumab plus Pertuzumab for HER2-amplified Advanced Colorectal Cancer: Results from the Drug Rediscovery Protocol (DRUP) - 2 month(s) ago
In 2-5% of patients with colorectal cancer (CRC), human epidermal growth factor 2 (HER2) is amplified or overexpressed. Despite prior evidence that an…
Source: www.sciencedirect.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 47Battle of the biopsies: Role of tissue and liquid biopsy in hepatocellular carcinoma - 3 month(s) ago
The diagnosis and management of hepatocellular carcinoma (HCC) have improved significantly in recent years. With the introduction of immunotherapy-bas…
Source: www.sciencedirect.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 47Battle of the biopsies: Role of tissue and liquid biopsy in hepatocellular carcinoma - 3 month(s) ago
The diagnosis and management of hepatocellular carcinoma (HCC) have improved significantly in recent years. With the introduction of immunotherapy-bas…
Source: www.sciencedirect.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 44Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial - 3 month(s) ago
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. To assess long-term risk of local tumor regrowth, we report updated organ preservation rate and oncologic outcomes of the OPRA trial (ClinicalTrials.gov identifier: NCT02008656). Patients with stage II/III rectal cancer were randomly assigned to receive induction chemotherapy followed by chemoradiation (INCT-CRT) or chemoradiation followed by consolidation chemotherapy (CRT-CNCT). Patients who achieved a complete or near-complete response after finishing treatment were offered watch-and-wait (WW). Total mesorectal excision (TME) was recommended for those who achieved an
Source: ascopubs.orgCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 18
BRAF V600 mutations are common in melanoma, thyroid, and non-small-cell lung cancers. Despite dabrafenib and trametinib being standard treatments for …
Source: www.sciencedirect.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 18
BRAF V600 mutations are common in melanoma, thyroid, and non-small-cell lung cancers. Despite dabrafenib and trametinib being standard treatments for …
Source: www.sciencedirect.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 57Radiological diagnosis of hepatocellular carcinoma does not preclude biopsy before treatment - 3 month(s) ago
The diagnosis of hepatocellular carcinoma (HCC) in patients with cirrhosis relies on non-invasive criteria based on international guidelines. The adve…
Source: www.sciencedirect.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 55Radiological diagnosis of hepatocellular carcinoma does not preclude biopsy before treatment - 3 month(s) ago
The diagnosis of hepatocellular carcinoma (HCC) in patients with cirrhosis relies on non-invasive criteria based on international guidelines. The adve…
Source: www.sciencedirect.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 13
The benefit of combination neoadjuvant and adjuvant chemotherapy and immune checkpoint inhibition in patients with locally advanced, resectable gastri…
Source: www.sciencedirect.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 50Radiological diagnosis of hepatocellular carcinoma does not preclude biopsy before treatment - 3 month(s) ago
The diagnosis of hepatocellular carcinoma (HCC) in patients with cirrhosis relies on non-invasive criteria based on international guidelines. The adve…
Source: www.sciencedirect.comCategories: General Medicine News, Oncologists2Tweet
RT @ArndtVogel: Trastuzumab + Pertuzumab for HER2-amplified CRC European J Cancer https://t.co/u19TYuw6ot 🔎DRUP protocol 🇳🇱, 24 pts RAS WT…